# China NMPA Drug Inspection - Kunming Jingtian Pharmaceutical Co., Ltd. - Drynaria fortunei

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/kunming-jingtian-pharmaceutical-co-ltd/8c7353f5-e2e9-4d56-9e37-0b27f855dd6b/
Source feed: China

> China NMPA drug inspection for Kunming Jingtian Pharmaceutical Co., Ltd. published December 29, 2020. Drug: Drynaria fortunei. The Guizhou Provincial Drug Administration released its fourth Drug Quality Announcement of 2020, documenting quality fa

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Drug Administration Drug Quality Bulletin (Drug Sampling Inspection Information Announcement) (Issue 4, 2020) (Total Issue 42)
- Company Name: Kunming Jingtian Pharmaceutical Co., Ltd.
- Publication Date: 2020-12-29
- Drug Name: Drynaria fortunei
- Inspection Finding: The non-compliance is due to issues with appearance and identification.
- Action Taken: Drug regulatory authorities at all levels shall, in accordance with relevant laws and regulations, investigate and prosecute drugs that fail to meet the standards in their jurisdictions, strengthen supervision of relevant entities, urge them to correct their illegal activities, and enhance risk prevention and control.
- Summary: The Guizhou Provincial Drug Administration released its fourth Drug Quality Announcement of 2020, documenting quality failures across four drug varieties. The inspections identified substandard products from three manufacturers: Bozhou Zhongqiang Traditional Chinese Medicine Pieces Co., Ltd., Kunming Jingtian Pharmaceutical Co., Ltd., and Jiangxi Heshuo Pharmaceutical Co., Ltd. The regulatory framework for these inspections included the Drug Administration Law of the People's Republic of China and the 2015 edition of the Chinese Pharmacopoeia. Key violations involved quality control issues in traditional Chinese medicine pieces, including excessive moisture in Gentian Root, identification and property discrepancies in Drynaria, high total ash content in Epimedium, and failed content determination in Salt-processed Psoralea. These issues reflect a failure to adhere to mandatory pharmaceutical standards. Following these results, the Guizhou Provincial Drug Administration ordered local regulatory departments to investigate and prosecute the responsible parties. The involved companies are required to implement immediate corrective actions and address illegal activities. Additionally, authorities must enhance supervision and risk prevention protocols to safeguard public health and ensure the safety of medications distributed throughout the province.

Company: https://www.globalkeysolutions.net/companies/kunming-jingtian-pharmaceutical-co-ltd/e21da34c-2a29-4bbf-9bb9-05e621ed0b33/